力尔凡联合长春瑞滨卡培他滨治疗晚期乳腺癌39例

目的:观察力尔凡联合长春瑞滨、卡培他滨方案治疗晚期乳腺癌的疗效及安全性。方法:39例有可测量病灶的转移性乳腺癌患者,按就诊先后顺序随机分为综合治疗组和对照组。对照组患者中心静脉持续滴注长春瑞滨,口服卡培他滨。综合治疗组在对照组用药的基础上加用力尔凡静脉滴注。结果:综合治疗组21例患者中CR2例(9.5%),PR6例(28.6%),MR4例(19.1%),总有效率为58.2%。对照组18例患者中,CR1例(5.6%),PR4例(22.2%),MR3例(16.6%),总有效率为44.4%。综合治疗组的有效率明显高于对照组,且不良反应的发生率低于对照组。结论:力尔凡联合长春瑞滨、卡培他滨治疗晚期乳腺癌,可以起到增效减毒作用,并且使长春瑞滨、卡培他滨作为二线方案治疗晚期乳腺癌,不良反应可以耐受。

Mannatide Combined with Vinorelbine and Capecitabine for Treating Advanced Breast Cancer

Objective:To observe the curative effect and safety of mannatide combined with vinorelbine and capecitabine on advanced breast cancer.Methods:39 patients with metastatic advanced breast cancer were randomly divided into two groups.Control group(n=18)received vinorelbine 6mg/m/d,d1-5 civ,cycles were repeated every 21 days,also received capecitabine for 2-4 cycles at the same time.In addition to the same regimen,treating group(n=21)accepted intravenous infusion of mannatide(10mg/d)for the first 3 days,then increased to the dose of 20mg/d for 8-12weeks.Results:In treatment and control groups,the effective rates were 58.2% and 44.4%(P<0.05),the rates of side effects in treatment group were less than in control group.Conclusions:Mannatide combined with vinorelbine and capecitabine is effective for advanced breast cancer and can reduce the side effects of vinorelbine plus capecitabine.